Ethics statement
A guardian of the patient provided written informed consent to participate, and this study was approved by the University of British Columbia Research Ethics Board as part of the
Personalized OncoGenomics trial (NCT02155621) and represents part of the Personalized OncoGenomics trial NCT02155621.
Conflict of interest: The authors declare no competing interests.
Acknowledgements: We gratefully acknowledge the participation of the patient and their family. This work would not be possible without the Personalized OncoGenomics (POG) team, Canada’s Michael Smith Genome Sciences Centre technical and project management platforms along with the generous support of the BC Cancer and BC Children’s Hospital Foundations. The results published here are in part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative phs000218, managed by the NCI available at https://portal.gdc.cancer.gov/, and the Treehouse Childhood Cancer Initiative (https://treehousegenomics.soe.ucsc.edu/). Information about TARGET can be found at https://ocg.cancer.gov/programs/target.
Author contribution: AL, JT, YS, DR and SC wrote the manuscript. AL and SC: collected clinical information. DR: performed radiology review. JT: provided pathological analysis. YS: performed bioinformatic analysis. DC, RR, RD and SC: provided patient treatment and clinical care. All authors read and approved the final manuscript.
Data availability statement: Data supporting the findings of this study are available from the corresponding author by request